CONMED Corp (CNMD) CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuation, electrosurgical interventions, and endomechanical applications. Its endoscopic technology segment provides both diagnostic and therapeutic instruments utilized in gastroenterological procedures, alongside products specifically designed for addressing conditions of the biliary system. The company also offers cardiac monitoring solutions, featuring ECG and EEG electrodes, and pads for cardiac defibrillation. CONMED distributes its diverse range of products directly to a wide array of healthcare facilities, including hospitals and surgical centers, and also leverages specialized medical distributors. Established in 1970, CONMED Corporation maintains its corporate headquarters in Largo, Florida.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
CONMED Corporation NYSE:CNMD Healthcare · Medical - Devices
CLOSED · Nov 9 $51.94 CLOSED · Nov 9 Prev close $51.50 Close $51.94 0.00% AH close $51.94 VOL 376K $ Vol $19.53M RVOL 0.85x
Mkt Cap $1.55B
VOL 376K sh
$ Vol $19.53M
RVOL 0.85×
Press Release
CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
CONMED will participate in the Jefferies Global Healthcare Conference, held November 16-19, 2026 in London, UK.
Management will join a fireside chat on November 16 at 6:30 a.m. ET, with a live webcast and roughly 90-day replay available on the company's investor relations site.
The release contains no financial figures or corporate announcements; watch the fireside chat for any incremental color on the medtech demand environment.
• 7d ago AI analysis › Press Release ⚠ 3
CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED reported Q3 2026 sales of $335.6 million, down 0.7% year-over-year as reported, but up 6.7% on an organic constant-currency basis excluding its exited GI product lines.
GAAP diluted EPS was $0.66 (up 613.7%) while adjusted diluted EPS was $1.04, down 3.2%; the CEO said adjusted EPS exceeded management's expectations on balanced Orthopedic and General Surgery contributions.
Full-year 2026 guidance was updated: net sales of $1,360M-$1,366M (narrowed from $1,358M-$1,373M) and adjusted diluted EPS of $4.54-$4.61 (raised at the low end from $4.48).
• 12d ago AI analysis › Press Release
CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026
CONMED Corporation will report third quarter 2026 financial results after market close on Wednesday, October 28, 2026.
Management will host a conference call at 4:30 p.m. ET that day, with a live webcast and replay available on the company's investor relations site.
The release contains no financial data or guidance; it is a routine scheduling notice ahead of the earnings report.
• 1mo ago AI analysis › Press Release
CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference
CONMED Corporation announced it will attend the Wells Fargo 21st Annual Healthcare Conference held in Boston from September 8-10.
Management is scheduled to participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time.
A live webcast of the session will be available on the company’s investor relations website, followed by a replay for approximately 90 days.
• 2mo ago AI analysis › Press Release ● Major
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED reported second quarter sales of $343.5 million, flat year-over-year as reported but increasing 6.0% on an organic constant currency basis.
Adjusted diluted EPS rose 20% to $1.38, exceeding the company’s expectations and driving an increase in full-year EPS guidance to $4.48-$4.60.
The company also appointed John E. Gallagher as CFO and announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s da Vinci 5 platform.
• 3mo ago AI analysis › Press Release
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
CONMED announced an expanded FDA indication for its AirSeal Robotic Solution to include use with Intuitive’s 8 mm hex cannulas for the da Vinci 5 platform.
This update extends the product’s compatibility across the full portfolio of Intuitive’s da Vinci X, Xi, and 5 robotic systems, reinforcing its utility in robotic surgery.
Management expects the milestone to provide marketplace clarity and support growth for the AirSeal portfolio by enabling consistent workflows with the latest platform architecture.
• 3mo ago AI analysis › Press Release
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
CONMED is presenting data at the Society of Robotic Surgery Annual Meeting comparing its AirSeal system to Stryker's PneumoClear.
The 40-patient trial demonstrated that AirSeal resulted in fewer nociceptive events (20.7 vs 33.5), shorter procedure times, and less blood loss.
The company will also host a session on low-pressure insufflation featuring surgeons Amit Taggar, Gabe Mena, Philip Woodworth, and Rahila Essani.
• 3mo ago AI analysis › Press Release
CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
CONMED Corporation will report its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026.
Management will host a conference call at 4:30 p.m. ET on the same day to discuss the quarterly results.
A live webcast of the call will be accessible via the Investors section of the company's website.
• 4mo ago AI analysis › Press Release
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer
CONMED Corporation named John E. Gallagher as its new Chief Financial Officer, effective July 15, 2026, succeeding Todd Garner who will stay on as an advisor through early November.
Gallagher brings nearly three decades of financial leadership experience, most recently serving as CFO of Certara and Cue Health, and previously holding senior finance roles at Becton, Dickinson & Co. for nine years.
CEO Patrick Beyer cited Gallagher's deep healthcare background and track record in supporting strategic initiatives as key factors in his selection to help drive long-term shareholder value.
• 4mo ago AI analysis › Press Release
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED appointed Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026.
The board size increases to nine directors, with Martin joining the Audit and Strategy Committees and Mirviss joining the Compensation and Governance Committees.
Both appointees bring deep MedTech experience from Johnson & Johnson and Boston Scientific, respectively, reinforcing the board's operational expertise.
• 5mo ago AI analysis › Press Release ⚠ 2
CONMED Corporation Announces First Quarter 2026 Financial Results
CONMED reported Q1 sales of $317.0 million, down 1.3% year-over-year due to the exit of GI products, while Adjusted EPS came in at $0.89.
Management raised its full-year 2026 organic revenue growth outlook to 5.0%–6.5% on a constant currency basis, up from 4.5%–6.0%, and updated total revenue guidance to $1.350B–$1.375B.
Despite higher-than-expected interest expenses from planned debt refinancing, the company reaffirmed its full-year Adjusted EPS guidance of $4.30 to $4.45.
• 6mo ago AI analysis › 
